The role of ICS in COPD is an area of intense interest, said Dr Gary Ferguson (Pulmonary Research Institute of Southeast Michigan, USA) at the beginning of his lecture . The recently updated GOLD guidelines recommend initiation of ICS treatment for patients with high exacerbation risk only , due to concerns over the risk:benefit ratio of chronic ICS use compared to other therapies. However, real-world studies have shown that ICS are prescribed across the spectrum of disease severity .
The benefits of ICS/LAMA/LABA triple therapy are not well studied in certain patient populations, such as patients who are considered to have a lower risk of exacerbations. Budesonide/glycopyrronium/formoterol metered-dose inhaler (MDI), formulated using an innovative co-suspension delivery technology, is a fixed-dose triple combination in development for patients with COPD. “KRONOS was partly a regulatory study to evaluate triple vs dual combination therapy”, stated Dr Ferguson. ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Treatments Targeting Type2-inflammation Next Article
From Clinical, Anatomical, Pathophysiological, and Inflammatory Subsets to Molecular Pathways »
Table of Contents: ERS 2018
COPD: Triple therapy, MABA and antibiotics
Current look on asthma
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.